Sector News

Monsanto bid may mean Bayer will cut pharma R&D spending

June 1, 2016
Energy & Chemical Value Chain

The proposed $62bn merger with agrochemical firm Monsanto would jeopardise Bayer’s pharmaceutical business, according to a BMI Research analyst.

> Read the full article on the in-Pharma Technologist website

By Dan Stanton

Source: in-Pharma Technologist

comments closed

Related News

July 21, 2024

PepsiCo and Yara partner to decarbonise European crop production

Energy & Chemical Value Chain

PepsiCo Europe and crop nutrition company Yara have announced a long-term partnership aimed at providing European farmers with low-carbon crop nutrition solutions to help decarbonise the food value chain. Under the agreement, Yara will supply PepsiCo with up to 165,000 tons of fertiliser per year by 2030, covering around 25% of the food and beverage giant’s crop fertiliser needs across Europe.

July 21, 2024

BASF sells Flocculants business for mining applications to Solenis

Energy & Chemical Value Chain

BASF has signed an agreement to sell its flocculants business for mining applications to Solenis, a specialty chemicals manufacturer. The divestment of the flocculants business to Solenis is part of BASF’s ongoing portfolio optimisation with the aim of focusing on strategic core areas.

July 21, 2024

ADAMA announces Gaël Hili as President and CEO replacing Steve Hawkins

Energy & Chemical Value Chain

ADAMA Ltd. a leading crop protection company, announced that its board of directors has appointed Gaël Hili as its President and Chief Executive Officer, effective October 1, 2024. Hili will join the Syngenta Group Leadership Team and will be based in Tel Aviv.

How can we help you?

We're easy to reach